- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr. Kolodziej Discusses The Use of Novel Treatments in Combination Therapy
Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, discusses the financial challenges associated with the combination of newer novel agents in breast cancer treatment.
Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, discusses the financial challenges associated with the combination of newer novel agents in breast cancer treatment. He suggests that more careful healthcare spending could support the high costs, and deliver the potential benefits of these drug combinations. "This situation is not unique to breast cancer," said Kolodziej. "You can extrapolate it to just about any disease we treat these days.
This video was taken on June 1, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
